Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Global Depression Drugs Industry Research Report and Forecast 2025 and Outlook

Global Depression Drugs Market Research Report

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/25/2020 -- The global depression drugs market is expected to register a CAGR over 5.5% over the estimated period. Anxiety is a normal reaction to stress, which helps to deal with tense situations, leading to depression situations. When anxiety turns out to be excessive and irrational extension of everyday conditions, it turns into disorder in various medical definitions. Panic attacks, a type of depression disorder, are associated with sudden episodes of emotions of fear and anxiety. These disorders are among the most prevalent depression disorders. Approximately one in four people suffers from depression disorder at some point in their lives owing to everyday stressful situations is dealt. Depression patients witness substantial physical and emotional discomfort and elevated rates of substance use and medical illnesses. Panic attacks, a frequent type of depression situation and disorder, are associated with sudden episodes of emotions of fear and anxiety.

Some of the key players operating in the market include: Novartis International AG, Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Abbott Laboratories, Allergan, Plc, MSI Methylation Sciences Inc., Luye Pharma Group Ltd. and H. Lundbeck A/S.

Sample@ https://www.arcognizance.com/enquiry-sample/1046652

Key psychiatric disorders, for instance major depressive disorder (MDD) or bipolar disorder, are associated with a more chronic and treatment refectory course and these patients are at an increased risk for suicide. Some of the factors leading to depression, include trauma, complicated relationships, childhood bad experiences, loss of a loved ones and daily life stressful situation. The global depression drugs market is also experiencing many repurposed and off-label drugs for their treatment. Traditional therapeutic approach has left with only partial treatment, resulting in a large number of untreated and partially treated populations. Therefore, to offset the impact of depression, many novel techniques and drugs have been developed to satisfy the demand for depression drugs in near decade. Rising demand for antidepressants owing to its minimum side effects and growing awareness levels amongst the consumers will supplement market growth by 2025.

However, patent expiration along with surge in rate of drug withdrawals as well as introduction of generic variants on a large scale might restrain might growth to some extent. Stringent regulations, particularly in Europe for the approval of depression drugs, patent expiry of several outselling antidepressants drugs and laws pertaining to the commercial usage of antidepressants without prescription might also impact the market growth in negative way. Retail pharmacies are key distribution channels of depression drugs. Furthermore, typical antipsychotics was the drug class that lead the market share in 2017 and is expected to continue to dominate the market for some time.

Purchase@ https://www.arcognizance.com/purchase/1046652

The global depression drugs market is bifurcated on the basis of medication class, brand and geography. The medication class segment is further divided into Tetracyclic Antidepressants (TeCAs), Anticonvulsants, Monoamine Oxidase Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), others. By brand, the market is segmented into Celexa, Zoloft, Cymbalta, Prozac, Others. Geographically, the market is divided into North America, Europe, Asia-Pacific (APAC), Latin America and Middle East & Africa (MEA). The Depression Drugs market has been further divided into key countries.

Table of Contents
Chapter One: Market Introduction

Chapter Two: Executive Summary

Chapter Three: Global Depression Drugs market – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints

Chapter Four: Global Depression Drugs market – Analysis and Revenue Forecast, 2015-2025 – Type
4.1. Tetracyclic Antidepressants (TeCAs)
4.2. Anticonvulsants
4.3. Monoamine Oxidase Inhibitors
4.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
4.5. Others

Chapter Five: Global Depression Drugs market – Analysis and Revenue Forecast, 2015-2025 – Brand
5.1. Celexa
5.2. Zoloft
5.3. Cymbalta
5.4. Prozac
5.5. Others

Chapter Six: Global Depression Drugs market – Analysis and Revenue Forecast, 2015-2025 – By Region
6.1. North America
6.2. Europe
6.3. Asia-Pacific
6.4. Latin America
6.5. Middle East & Africa

Chapter Seven: North America Depression Drugs market – Analysis and Revenue Forecast, 2015-2025
7.1. North America Depression Drugs market – By Application, 2015-2025
7.1.1. Tetracyclic Antidepressants (TeCAs)
7.1.2. Anticonvulsants
7.1.3. Monoamine Oxidase Inhibitors
7.1.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
7.1.5. Others
7.2. North America Depression Drugs market – By Brand, 2015-2025
7.2.1. Celexa
7.2.2. Zoloft
7.2.3. Cymbalta
7.2.4. Prozac
7.2.5. Others
7.3. North America Depression Drugs market – By Country, 2015-2025
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico

Chapter Eight: Europe Depression Drugs market – Analysis and Revenue Forecast, 2015-2025
8.1. Europe Depression Drugs market – By Application, 2015-2025
8.1.1. Tetracyclic Antidepressants (TeCAs)
8.1.2. Anticonvulsants
8.1.3. Monoamine Oxidase Inhibitors
8.1.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
8.1.5. Others
8.2. Europe Depression Drugs market – By Brand, 2015-2025
8.2.1. Celexa
8.2.2. Zoloft
8.2.3. Cymbalta
8.2.4. Prozac
8.2.5. Others
8.3. Europe Depression Drugs market – By Country, 2015-2025
8.3.1. Germany
8.3.2. France
8.3.3. UK
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe

Chapter Nine: Asia-Pacific Depression Drugs market – Analysis and Revenue Forecast, 2015-2025
9.1. Asia Pacific Depression Drugs market – By Application, 2015-2025
9.1.1. Tetracyclic Antidepressants (TeCAs)
9.1.2. Anticonvulsants
9.1.3. Monoamine Oxidase Inhibitors
9.1.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
9.1.5. Others
9.2. Asia Pacific Depression Drugs market – By Brand, 2015-2025
9.2.1. Celexa
9.2.2. Zoloft
9.2.3. Cymbalta
9.2.4. Prozac
9.2.5. Others
9.3. Asia-Pacific Depression Drugs market – By Country, 2015-2025
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Rest of Asia-Pacific

Chapter Ten: Latin America Depression Drugs market – Analysis and Revenue Forecast, 2015-2025
10.1. Latin America Depression Drugs market – By Application, 2015-2025
10.1.1. Tetracyclic Antidepressants (TeCAs)
10.1.2. Anticonvulsants
10.1.3. Monoamine Oxidase Inhibitors
10.1.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
10.1.5. Others
10.2. Latin America Depression Drugs market – By Brand, 2015-2025
10.2.1. Celexa
10.2.2. Zoloft
10.2.3. Cymbalta
10.2.4. Prozac
10.2.5. Others
10.3. Latin America Depression Drugs market – By Country, 2015-2025
10.3.1. Brazil
10.3.2. Rest of Latin America

Chapter Eleven: Middle East & Africa Depression Drugs market – Analysis and Revenue Forecast, 2015-2025
11.1. MEA Depression Drugs market – By Application, 2015-2025
11.1.1. Tetracyclic Antidepressants (TeCAs)
11.1.2. Anticonvulsants
11.1.3. Monoamine Oxidase Inhibitors
11.1.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
11.1.5. Others
11.2. MEA Depression Drugs market – By Brand, 2015-2025
11.2.1. Celexa
11.2.2. Zoloft
11.2.3. Cymbalta
11.2.4. Prozac
11.2.5. Others
11.3. Middle East & Africa Depression Drugs market – By Country, 2015-2025
11.3.1. UAE
11.3.2. Saudi Arabia
11.3.3. Turkey
11.3.4. Rest of Middle East & Africa

Chapter Twelve: Competitive Analysis
12.1.1. Competition Dashboard
12.1.2. Company Profiles
12.1.2.1. Novartis International AG
12.1.2.1.1. Company Details
12.1.2.1.2. Product Portfolio
12.1.2.1.3. Financial Overview
12.1.2.1.4. Main Business Overview
12.1.2.1.5. News
12.1.2.2. Janssen Pharmaceuticals, Inc.
12.1.2.3. Lupin Pharmaceuticals, Inc.
12.1.2.4. Abbott Laboratories
12.1.2.5. Allergan, Plc
12.1.2.6. MSI Methylation Sciences Inc.
12.1.2.7. Luye Pharma Group Ltd.
12.1.2.8. H. Lundbeck A/S

Chapter Thirteen: Appendix

Chapter Fourteen: Research Conclusions

About Analytical Research Cognizance
Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARC's potential.
ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-depression-drugs-industry-research-report-and-forecast-2025-and-outlook-1294935.htm

Media Relations Contact

Ranjeet Dengale
Director Sales
Analytical Research Cognizance
Telephone: 1-646-403-4695
Email: Click to Email Ranjeet Dengale
Web: https://www.arcognizance.com/

Latest News
Top News